Salute e Benessere

Next Generation Antibody Therapeutics Market Size will Hit $22.88 Billion by…

Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/next-generation-antibody-therapeutics-market?kailas Download Exclusive Sample Report:https://www.datamintelligence.com/download-sample/next-generation-antibody-therapeutics-market?kailas Industry Trends and Recent Developments: Segmentation Analysis By Technology In 2024, antibody-drug conjugates held the largest market share, accounting for more than one-third of revenues, valued at...
PR Newswire
09/09/2025

Neurolief Announces Publication of Groundbreaking MOOD Study Demonstrating…

Key Findings: Key Findings: "This publication marks a major milestone for both Neurolief and for the field of mental health," saidScott Drees, Chief Executive Officer at Neurolief. "The MOOD study validates our vision of delivering effective, accessible, and personalized neuromodulation therapy to patients suffering from MDD. We are now one step closer to makingProliv™Rxavailable to millions in need." Dr.Linda Carpenter, Principal Investigator of the MOOD study, added: ...
PR Newswire
09/09/2025

CAS introduces CAS IP Finder for improved intellectual property search

CAS IP Finder™ introduces AI-enhanced features and expanded content to make precision search more accessible across broader teams. The solution launches in fall 2025, with additional capabilities to follow. Developed to support evolving organizational search needs in intellectual property, CAS IP Finder enables organizations to uncover insights faster, reduce risk, and make confident decisions. Patent volume continues to grow, scientific disciplines are increasingly interconnected,...
PR Newswire
09/09/2025

Metabolon Partners with China Kadoorie Biobank to Advance Precision Health

Historically, clinical trials and population health studies have focused on white European participants, neglecting the diversity of other racial and ethnic groups. This partnership addresses the need to study underrepresented ethnic groups to improve our understanding of health and disease and will generate robust evidence on the lifestyle, environmental, and genetic factors influencing a wide range of common diseases. The insights gained from this study will be instrumental in advancing global…
PR Newswire
09/09/2025

Inizio appoints Ryan Quigley as its new Chief Executive Officer to lead its next…

With $1.6bn in revenue and more than 10,500 employees across five connected business units, Medical, Advisory, Evoke, Engage and Biotech, Inizio partners at scale with more than 700 large pharma and biotech clients globally to support their clinical development and commercialization journeys, improving patient access and experience. Inizio brings a fully connected suite of technology-enabled capabilities, combined with specialized scientific expertise across all therapeutic areas, to support…
PR Newswire
09/09/2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of…

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally...
Nasdaq GlobeNewswire
09/09/2025

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market. About Foralumab Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has...
Nasdaq GlobeNewswire
09/09/2025

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as…

Numab Therapeutics AG(“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced that David Urech, Ph.D., Chief Executive Officer and co-founder of Numab, will transition from his position as CEO and continue as a member of the Board of Directors and Chair of the R&D Committee. As part of the planned leadership transition, Numab has appointed industry veteran Barbara Angehrn Pavik as CEO and member of the...
Nasdaq GlobeNewswire
09/09/2025

Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing…

The ongoing Phase 1 trial is a multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TGW101 in patients with relapsed or refractory solid tumors. The primary objectives are to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and dose regimen for cohort expansion. The ongoing Phase 1 trial is a multicenter, open-label, dose-escalation study designed to evaluate the…
PR Newswire
09/09/2025

Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic…

ALGS is a rare genetic disorder that can affect multiple organ systems, including the liver, heart, skeleton, eyes and kidneys.i It is estimated that ALGS is present in 1 in every 30,000 live births.ii Most of those living with ALGS experience cholestatic pruritus which can significantly impair sleep and quality of life. ALGS is a rare genetic disorder that can affect multiple organ systems, including the liver, heart, skeleton, eyes and kidneys. iIt is estimated that ALGS is present in 1 in...
PR Newswire
09/09/2025

Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor…

NEW YORK and PARIS, Sept.09, 2025(GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial conducted in collaboration with Prof. Filippo Lococo’s team at Policlinico Gemelli in Rome.Circulating Tumor Cells (CTCs) are well-established, non-invasive cancer markers, but clinical use of CTC-DNA assays has been limited by sensitivity,...
Nasdaq GlobeNewswire
09/09/2025

Havas Health Network Announces Two Senior Strategic Appointments

"Christina and Ayesha represent the caliber of strategic leadership that defines the future of Havas Health Network, and we're thrilled to welcome them to our leadership team," said Brian Robinson, Global Chief Strategy Officer and Head of Growth, Havas Health Network. "As our network expands and the industry evolves, we're investing in leaders who understand the complexities of health, culture, and data, and can shape that knowledge into market-transforming work."…
PR Newswire
09/09/2025

CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Assumes…

CHAPPER healthcare,AscellaHealth’sglobal pharmaceutical wholesaler, distributor and commercialization service provider, announces its appointment as president ofEUROPACCESS, a strategic joint venture of seven pharmaceutical service providers across Europe. Offering integrated, commercialisation and market access solutions to help navigate the complex healthcare systems throughout Europe, EUROPACCESS draws upon the leadership role of CHAPPER healthcare and its 50-year legacy of...
Nasdaq GlobeNewswire
09/09/2025

BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025

Gunilla Osswald trained as a pharmacist and earned a PhD at Uppsala University. Since 2014, she has served as CEO of BioArctic. Earlier this year, on March 12, 2025, Gunilla Osswald, together with BioArctic's two founders, Lars Lannfelt and Pär Gellerfors, was awarded Uppsala University's Innovation and Entrepreneurship Prize for successfully addressing a growing global health problem through their work in developing the drug lecanemab, which slows the progression of Alzheimer's disease. ...
PR Newswire
09/09/2025

LUMICKS launches Avidion to improve cell therapy development

83% of CAR-T cell therapies fail after preclinical development [1], highlighting that current in vitro assays and animal models too often fail to predict clinical efficacy. Molecular assays measure how receptors bind antigens, while killing assays measure the functional outcomes. There is a gap in-between that captures how cells physically engage and interact. This leaves a critical blind spot in understanding the mechanism of action and selecting the best candidates. Cell Avidity, the combined…
PR Newswire
09/09/2025

Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr…

LONDON, Sept. 9, 2025 /PRNewswire/ -- Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of accomplished oncology expert and biotech innovator, Samuel Blackman, MD, PhD, as an independent, Non-Executive Director to its Board. LONDON , Sept. 9, 2025 /PRNewswire/ -- Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate...
PR Newswire
09/09/2025

Results from BIG D-FOOT study using STIMULAN® when treating DFO to be presented…

The Biocomposites symposium, titled "From diabetic foot osteomyelitis to peri-prosthetic joint infection: what are the most appropriate treatment strategies?", will be moderated by Dr Massimiliano De Paolis and Professor Pierluigi Viale, and will feature leading clinicians discussing innovations in infection management for complex and high-risk patient groups. The Biocomposites symposium, titled"From diabetic foot osteomyelitis to peri-prosthetic joint infection: what are the most…
PR Newswire
09/09/2025

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at…

"These results represent a significant advancement in MET-targeted therapy," said Dr. Cecilia Ahlin, CMO of DeuterOncology. "Our deuteration strategy has successfully enhanced drug exposure while maintaining efficacy, but most importantly, we have achieved this without the debilitating peripheral oedema that forces many patients to discontinue current MET inhibitors —symptoms that can severely limit daily activities such as walking, dressing, or cooking. This addresses a critical…
PR Newswire
09/09/2025

Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against…

The study, conducted solely by Kling Bio, utilized immortalized B-cell libraries derived from human peripheral blood mononuclear cells (PBMCs) and tonsil tissue to identify B-cell clones with cross-reactive neutralization against SARS-CoV-2 variants. Immortalization was achieved via retroviral transduction with apoptosis inhibitors, resulting in the libraries retaining full immunoglobulin isotype representation, enabling broad functional screening. High-throughput screening of 40,000 B-cells per…
PR Newswire
09/09/2025

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for…

Supported by a €2.5 million grant from the EIC Accelerator as part of the FRAXCURE project (Grant agreement No. 101217931), CONNECTA is one of just 71 companies selected from over 1,200 applicants in the October 2024 call, highlighting its innovative potential. The grant will enable CONNECTA to complete critical regulatory and preclinical activities, including safety studies, development of an age-appropriate oral formulation, and submission of its Pediatric Investigation Plan to support…
PR Newswire
09/09/2025

Bayer Foundation Backs 15 Women Entrepreneurs Scaling Urgent Healthcare and Food…

Selected from 1,763 applicants across 117 countries, the 2025 winners are advancing innovations from AI-powered health diagnostics and climate-resilient farming to community-led nutrition models and circular economy approaches. Selected from 1,763 applicants across 117 countries, the 2025 winners are advancing innovations from AI-powered health diagnostics and climate-resilient farming to community-led nutrition models and circular economy approaches. Since 2021, the Award has supported...
PR Newswire
09/09/2025

iOnctura Expands Roginolisib Trials to the US, Advancing Multi-Indication…

Roginolisib, an orally dosed small molecule allosteric modulator of PI3Kδ, is being investigated in multiple randomized Phase II studies in solid and hematological malignancies. The global Phase II randomized OCULE-01 study (NCT06717126) will assess whether roginolisib improves overall survival in patients with metastatic uveal melanoma who have progressed on prior therapy. Patients from both the US and Europe are now being treated in the study, which started in March 2025. Roginolisib, an...
PR Newswire
09/09/2025

Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and…

Alchemab's proprietary, AI-enabled platform is transforming drug discovery by identifying protective auto-antibodies and novel targets from individuals that are naturally resilient to various diseases. The platform operates like a search engine for the immune system, leveraging advanced machine learning models and proprietary data to interrogate the largest database of patient-derived antibodies, known as the DataCube, comprising over 6,000 highly curated patient samples from more than 30 global…
PR Newswire
09/09/2025

Nomination Committee of AB SKF for the Annual General Meeting 2026

The Annual General Meeting of AB SKF will be held in Gothenburg on Tuesday, 21 April 2026. The Annual General Meeting of AB SKF will be held inGothenburgon Tuesday,21 April 2026. Shareholders who wish to submit proposals to the Nomination Committee may contact the Chair of the Board of AB SKF on e-mail:[email protected]. Aktiebolaget SKF (publ) For further information, please contact:Press Relations: Carl Bjernstam, +46 31-337 2517; +46 722 201 893;carl.bjernstam@skf...
PR Newswire
09/09/2025
Altri  Comunicati